MSI-H TUMORS

Clinical trials for MSI-H TUMORS explained in plain language.

Never miss a new study

Get alerted when new MSI-H TUMORS trials appear

Sign up with your email to follow new studies for MSI-H TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New combo tackles resistant cancers in small trial

Disease control Ongoing

This study tests whether combining two immunotherapy drugs, nivolumab and relatlimab, can shrink or control advanced solid tumors with a specific genetic feature (MSI-H) that have stopped responding to prior PD-(L)1 therapy. About 38 adults with these hard-to-treat cancers will r…

Matched conditions: MSI-H TUMORS

Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control

Last updated May 17, 2026 06:47 UTC

MSI-H TUMORS

Get alerted when new MSI-H TUMORS trials appear

New combo tackles resistant cancers in small trial